omeprazole has been researched along with sulfaphenazole in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (25.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Afzelius, L; Andersson, TB; Baroni, M; Cruciani, G; Karlén, A; Masimirembwa, CM; Mecucci, S; Zamora, I | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Dai, R; Liu, Y; She, M; Wu, Z | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Chen, F; Chen, W; Lan, L; Li, B; Li, J; Liu, Y; Mao, F; Ni, S; Wei, H; Zhu, J | 1 |
| Chen, LZ; Huang, X; Liu, MM; Liu, XH; Ma, D; Shi, JB; Shu, HY; Wu, J; Yu, YL | 1 |
| Binkley, SN; Ring, BJ; VandenBranden, M; Wrighton, SA | 1 |
| Checovich, WJ; Guengerich, FP; Inoue, K; Shaw, PM; Shimada, T; Yamazaki, H | 1 |
| Greenblatt, DJ; Venkatakrishnan, K; von Moltke, LL | 1 |
| Kitamura, S; Konishi, T; Nishikawa, H; Taguchi, K | 1 |
| Greenblatt, DJ; Hesse, LM; Shader, RI; Venkatakrishnan, K; von Moltke, LL | 1 |
| Giancarlo, GM; Granda, BW; Greenblatt, DJ; Venkatakrishnan, K; von Moltke, LL | 1 |
| Farid, NA; Hagihara, K; Ikeda, T; Ishizuka, T; Kazui, M; Kurihara, A; Nishiya, Y; Okazaki, O | 1 |
| Burmistrova, OA; Poloznikov, AA; Sakharov, DA; Shkurnikov, MY; Zakhariants, AA | 1 |
16 other study(ies) available for omeprazole and sulfaphenazole
| Article | Year |
|---|---|
Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors.
Topics: Amino Acids; Aryl Hydrocarbon Hydroxylases; Binding Sites; Cytochrome P-450 CYP2C9; Enzyme Inhibitors; Models, Molecular; Molecular Conformation; Molecular Structure; Quantitative Structure-Activity Relationship | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors.
Topics: Cytochrome P-450 Enzyme Inhibitors; Enzyme Activation; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Molecular Structure; Recombinant Proteins; Stereoisomerism; Structure-Activity Relationship; Substrate Specificity | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.
Topics: Animals; Drug Design; Enzyme Inhibitors; ERG1 Potassium Channel; HEK293 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Mice; Oxidoreductases; Rats; Safety; Solubility; Structure-Activity Relationship; Water | 2018 |
Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis.
Topics: Administration, Oral; Animals; Arthritis; Cells, Cultured; Dimerization; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Development; Enzyme Inhibitors; Freund's Adjuvant; Humans; Lipopolysaccharides; Male; Mice; Molecular Structure; Nitric Oxide; Nitric Oxide Synthase Type II; Pyrazoles; Pyrimidines; Rats; Rats, Sprague-Dawley; RAW 264.7 Cells; Structure-Activity Relationship | 2021 |
Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Coumarins; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2E1; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Kinetics; Liver; Mephenytoin; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Proton-Translocating ATPases; Rabbits; Rabeprazole; Recombinant Proteins; Sulfaphenazole; Theophylline | 1996 |
Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
Topics: Animals; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Fluvoxamine; Humans; Hydroxylation; Ketoconazole; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Rabbits; Recombinant Proteins; Sulfaphenazole | 1997 |
Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity.
Topics: Benzoflavones; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Humans; In Vitro Techniques; Microsomes, Liver; Omeprazole; Phenacetin; Protein Isoforms; Reproducibility of Results; Sulfaphenazole | 1998 |
Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Benzoflavones; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Combinations; Drugs, Chinese Herbal; Enzyme Inhibitors; Glycyrrhiza; Humans; Isoenzymes; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Paeonia; Phenylpropionates; Quinidine; Recombinant Proteins; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Sulfaphenazole; Troleandomycin | 1999 |
CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.
Topics: Anti-Anxiety Agents; Benzoflavones; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Flunitrazepam; Humans; Hydroxylation; Isoenzymes; Ketoconazole; Kinetics; Methylation; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Quinidine; Ritonavir; Sulfaphenazole; Transfection | 2001 |
Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
Topics: Anti-Infective Agents; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Fibrinolytic Agents; Humans; Hydroxylation; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Phenytoin; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Sulfaphenazole; Ticlopidine | 2001 |
Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
Topics: Antibodies; Aryl Hydrocarbon Hydroxylases; Biocatalysis; Biotransformation; Cell Line; Cell Line, Tumor; Clopidogrel; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Glutathione; Humans; Ketoconazole; Kinetics; Mephenytoin; Microsomes; Microsomes, Liver; NADP; Omeprazole; Oxidation-Reduction; Oxidoreductases, N-Demethylating; Platelet Aggregation Inhibitors; Sulfaphenazole; Theophylline; Ticlopidine | 2010 |
Development of a Specific Substrate-Inhibitor Panel (Liver-on-a-Chip) for Evaluation of Cytochrome P450 Activity.
Topics: Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Humans; Ketoconazole; Lab-On-A-Chip Devices; Liver; Mass Spectrometry; Mephenytoin; Microsomes, Liver; Omeprazole; Phencyclidine; Substrate Specificity; Sulfaphenazole; Testosterone; Tolbutamide | 2016 |